Plain-English translation of NCT07715630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called PICX Injection—a type of immune cell therapy designed to fight multiple myeloma that has come back or stopped responding to standard drugs. Researchers will give you a single infusion of this medication and then closely monitor how well it works and how safe it is. The study will follow you for up to 2 years to see how long the benefits last.
Multiple myeloma can become resistant to standard treatments, leaving patients with few good options. This trial exists to see whether this new immune cell approach—which trains your own cells to recognize and attack myeloma—can help patients whose disease has stopped responding to other medicines.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication in the hospital. After the infusion, you will stay in the hospital for close observation and monitoring for side effects. You will then have regular follow-up appointments and blood tests over the next 2 years to track how well the treatment is working and to check for any long-term effects. The entire study period lasts up to 2 years from your treatment date.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China